Investment Philosophy
Make biotech understandable, useful, and memorable. Evidence-driven ratings from Strong Sell to Strong Buy when a company, stock, clinical readout, or catalyst is on the table. Flexible article modes: breaking news, FDA decisions, clinical data readouts, deep dives, science explainers, bear cases, bull cases, trial failures, and financing pieces. Voice stays consistent; structure adapts to the story.
About Gene Poole
The Biotech Booomer. PhD scientist writing about biotech, pharma, drug development, genetics, medicine, FDA decisions, clinical trials, scientific breakthroughs, failed trials, and the strange little circus where biology meets money. Patients before tickers. Data beat adjectives. Occasional offender in bad science puns.